Genetic polymorphisms of TP53 (rs1042522) and MDM2 (rs2279744) and colorectal cancer risk: An updated meta-analysis based on 59 case-control studies
•A significant association of TP53 (rs1042522) polymorphism with increased CRC risk in overall pooled subjects under recessive model was observed.•An evidence of MDM2 (rs2279744) association with increased CRC risk in overall pooled subjects under dominant and heterozygote models was observed.•TP53...
Gespeichert in:
| Veröffentlicht in: | Gene 2020-04, Vol.734, p.144391-144391, Article 144391 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 144391 |
|---|---|
| container_issue | |
| container_start_page | 144391 |
| container_title | Gene |
| container_volume | 734 |
| creator | Elshazli, Rami M. Toraih, Eman A. Elgaml, Abdelaziz Kandil, Emad Fawzy, Manal S. |
| description | •A significant association of TP53 (rs1042522) polymorphism with increased CRC risk in overall pooled subjects under recessive model was observed.•An evidence of MDM2 (rs2279744) association with increased CRC risk in overall pooled subjects under dominant and heterozygote models was observed.•TP53 (rs1042522) and MDM2 (rs2279744) variants might represent candidate risk factors for CRC susceptibility.
Several earlier reports implicated TP53 (rs1042522) and MDM2 (rs2279744) variants in outcome of colorectal cancer (CRC), but with inconclusive findings. This current meta-analysis designed to uncover the role of these variants in CRC risk.
Two independent investigators extracted 59 eligible case-control studies from different electronic databases involving Scopus, Web of Science and PubMed prior to June 2019. Pooled odds ratios (ORs) and “95% confidence intervals (CIs)” were computed for different hereditary models. Stratification and heterogeneity analyses, and “Begg’s funnel plots” were conducted. In silico data analyses of the functional and structural properties of the study variants were applied.
In general, 47 and 16 case-control reports for TP53 (11,589 patients and 13,622 controls) and MDM2 (6841 CRC patients and 8792 healthy controls), respectively were enrolled in this meta-analysis. A significant association of TP53 (rs1042522) variant with increased CRC risk in overall pooled subjects under recessive model [(CC vs. GC + GG, OR = 1.134, 95% CI = 1.006–1.278, P = 0.039)] was observed. Moreover, an evidence of MDM2 (rs2279744) association with increased CRC risk in overall pooled subjects under dominant and heterozygote models [(TG + GG vs. TT, OR = 1.120, 95% CI = 1.003–1.250, P = 0.044) and (TG vs. TT, OR = 1.189, 95% CI = 1.076–1.313, P = 0.001), respectively] was reported. Additionally, TP53 (rs1042522) and MDM2 (rs2279744) showed an association with CRC risk among Asians and Africans under a recessive model, and among Asians under different genetic models, respectively, by stratification analysis.
TP53 (rs1042522) and MDM2 (rs2279744) variants might represent candidate risk factors for CRC susceptibility. |
| doi_str_mv | 10.1016/j.gene.2020.144391 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2350095854</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0378111920300603</els_id><sourcerecordid>2350095854</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-7d52c2d7eff9753c1b5df49cad31590df8524b36dc722a305aa7a672da68bedb3</originalsourceid><addsrcrecordid>eNp9kc1u1TAUhC1ERS-FF2CBvGwXufgnjhPEpipQkFq1i7K2HPsEfEni4JMg3ffoA-MohSXeHOnTzEieIeQNZ3vOePXusP8OI-wFExmUpWz4M7LjtW4KxmT9nOyY1HXBOW9OyUvEA8tPKfGCnErBGJda7sjjdY6Yg6NT7I9DTNOPgAPS2NGHeyXpeULOSqGEuKB29PT2461YoRC60WW5QRf7mMDNtqfOjg4STQF_vqeXI10mb2fwdIDZFna0_RED0tZiZnGkqskOhMLFcU6xpzgvPgC-Iied7RFeP90z8u3zp4erL8XN3fXXq8ubwklVzYX2SjjhNXRdo5V0vFW-KxtnveSqYb6rlShbWXmnhbCSKWu1rbTwtqpb8K08I-db7pTirwVwNkNAB31vR4gLGiEVY42qVZmlYpO6FBETdGZKYbDpaDgz6xrmYNY1zLqG2dbIprdP-Us7gP9n-Vt_FnzYBJB_-TtAMugC5Ap9WAs1Pob_5f8BgUmY8A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2350095854</pqid></control><display><type>article</type><title>Genetic polymorphisms of TP53 (rs1042522) and MDM2 (rs2279744) and colorectal cancer risk: An updated meta-analysis based on 59 case-control studies</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Elshazli, Rami M. ; Toraih, Eman A. ; Elgaml, Abdelaziz ; Kandil, Emad ; Fawzy, Manal S.</creator><creatorcontrib>Elshazli, Rami M. ; Toraih, Eman A. ; Elgaml, Abdelaziz ; Kandil, Emad ; Fawzy, Manal S.</creatorcontrib><description>•A significant association of TP53 (rs1042522) polymorphism with increased CRC risk in overall pooled subjects under recessive model was observed.•An evidence of MDM2 (rs2279744) association with increased CRC risk in overall pooled subjects under dominant and heterozygote models was observed.•TP53 (rs1042522) and MDM2 (rs2279744) variants might represent candidate risk factors for CRC susceptibility.
Several earlier reports implicated TP53 (rs1042522) and MDM2 (rs2279744) variants in outcome of colorectal cancer (CRC), but with inconclusive findings. This current meta-analysis designed to uncover the role of these variants in CRC risk.
Two independent investigators extracted 59 eligible case-control studies from different electronic databases involving Scopus, Web of Science and PubMed prior to June 2019. Pooled odds ratios (ORs) and “95% confidence intervals (CIs)” were computed for different hereditary models. Stratification and heterogeneity analyses, and “Begg’s funnel plots” were conducted. In silico data analyses of the functional and structural properties of the study variants were applied.
In general, 47 and 16 case-control reports for TP53 (11,589 patients and 13,622 controls) and MDM2 (6841 CRC patients and 8792 healthy controls), respectively were enrolled in this meta-analysis. A significant association of TP53 (rs1042522) variant with increased CRC risk in overall pooled subjects under recessive model [(CC vs. GC + GG, OR = 1.134, 95% CI = 1.006–1.278, P = 0.039)] was observed. Moreover, an evidence of MDM2 (rs2279744) association with increased CRC risk in overall pooled subjects under dominant and heterozygote models [(TG + GG vs. TT, OR = 1.120, 95% CI = 1.003–1.250, P = 0.044) and (TG vs. TT, OR = 1.189, 95% CI = 1.076–1.313, P = 0.001), respectively] was reported. Additionally, TP53 (rs1042522) and MDM2 (rs2279744) showed an association with CRC risk among Asians and Africans under a recessive model, and among Asians under different genetic models, respectively, by stratification analysis.
TP53 (rs1042522) and MDM2 (rs2279744) variants might represent candidate risk factors for CRC susceptibility.</description><identifier>ISSN: 0378-1119</identifier><identifier>EISSN: 1879-0038</identifier><identifier>DOI: 10.1016/j.gene.2020.144391</identifier><identifier>PMID: 32001373</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Colorectal cancer ; Colorectal Neoplasms - genetics ; Genetic Predisposition to Disease ; Humans ; MDM2 ; Meta-analysis ; Polymorphism, Single Nucleotide ; Proto-Oncogene Proteins c-mdm2 - genetics ; TP53 ; Tumor Suppressor Protein p53 - genetics ; Variants</subject><ispartof>Gene, 2020-04, Vol.734, p.144391-144391, Article 144391</ispartof><rights>2020 Elsevier B.V.</rights><rights>Copyright © 2020 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-7d52c2d7eff9753c1b5df49cad31590df8524b36dc722a305aa7a672da68bedb3</citedby><cites>FETCH-LOGICAL-c356t-7d52c2d7eff9753c1b5df49cad31590df8524b36dc722a305aa7a672da68bedb3</cites><orcidid>0000-0002-3381-2641</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0378111920300603$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32001373$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Elshazli, Rami M.</creatorcontrib><creatorcontrib>Toraih, Eman A.</creatorcontrib><creatorcontrib>Elgaml, Abdelaziz</creatorcontrib><creatorcontrib>Kandil, Emad</creatorcontrib><creatorcontrib>Fawzy, Manal S.</creatorcontrib><title>Genetic polymorphisms of TP53 (rs1042522) and MDM2 (rs2279744) and colorectal cancer risk: An updated meta-analysis based on 59 case-control studies</title><title>Gene</title><addtitle>Gene</addtitle><description>•A significant association of TP53 (rs1042522) polymorphism with increased CRC risk in overall pooled subjects under recessive model was observed.•An evidence of MDM2 (rs2279744) association with increased CRC risk in overall pooled subjects under dominant and heterozygote models was observed.•TP53 (rs1042522) and MDM2 (rs2279744) variants might represent candidate risk factors for CRC susceptibility.
Several earlier reports implicated TP53 (rs1042522) and MDM2 (rs2279744) variants in outcome of colorectal cancer (CRC), but with inconclusive findings. This current meta-analysis designed to uncover the role of these variants in CRC risk.
Two independent investigators extracted 59 eligible case-control studies from different electronic databases involving Scopus, Web of Science and PubMed prior to June 2019. Pooled odds ratios (ORs) and “95% confidence intervals (CIs)” were computed for different hereditary models. Stratification and heterogeneity analyses, and “Begg’s funnel plots” were conducted. In silico data analyses of the functional and structural properties of the study variants were applied.
In general, 47 and 16 case-control reports for TP53 (11,589 patients and 13,622 controls) and MDM2 (6841 CRC patients and 8792 healthy controls), respectively were enrolled in this meta-analysis. A significant association of TP53 (rs1042522) variant with increased CRC risk in overall pooled subjects under recessive model [(CC vs. GC + GG, OR = 1.134, 95% CI = 1.006–1.278, P = 0.039)] was observed. Moreover, an evidence of MDM2 (rs2279744) association with increased CRC risk in overall pooled subjects under dominant and heterozygote models [(TG + GG vs. TT, OR = 1.120, 95% CI = 1.003–1.250, P = 0.044) and (TG vs. TT, OR = 1.189, 95% CI = 1.076–1.313, P = 0.001), respectively] was reported. Additionally, TP53 (rs1042522) and MDM2 (rs2279744) showed an association with CRC risk among Asians and Africans under a recessive model, and among Asians under different genetic models, respectively, by stratification analysis.
TP53 (rs1042522) and MDM2 (rs2279744) variants might represent candidate risk factors for CRC susceptibility.</description><subject>Colorectal cancer</subject><subject>Colorectal Neoplasms - genetics</subject><subject>Genetic Predisposition to Disease</subject><subject>Humans</subject><subject>MDM2</subject><subject>Meta-analysis</subject><subject>Polymorphism, Single Nucleotide</subject><subject>Proto-Oncogene Proteins c-mdm2 - genetics</subject><subject>TP53</subject><subject>Tumor Suppressor Protein p53 - genetics</subject><subject>Variants</subject><issn>0378-1119</issn><issn>1879-0038</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc1u1TAUhC1ERS-FF2CBvGwXufgnjhPEpipQkFq1i7K2HPsEfEni4JMg3ffoA-MohSXeHOnTzEieIeQNZ3vOePXusP8OI-wFExmUpWz4M7LjtW4KxmT9nOyY1HXBOW9OyUvEA8tPKfGCnErBGJda7sjjdY6Yg6NT7I9DTNOPgAPS2NGHeyXpeULOSqGEuKB29PT2461YoRC60WW5QRf7mMDNtqfOjg4STQF_vqeXI10mb2fwdIDZFna0_RED0tZiZnGkqskOhMLFcU6xpzgvPgC-Iied7RFeP90z8u3zp4erL8XN3fXXq8ubwklVzYX2SjjhNXRdo5V0vFW-KxtnveSqYb6rlShbWXmnhbCSKWu1rbTwtqpb8K08I-db7pTirwVwNkNAB31vR4gLGiEVY42qVZmlYpO6FBETdGZKYbDpaDgz6xrmYNY1zLqG2dbIprdP-Us7gP9n-Vt_FnzYBJB_-TtAMugC5Ap9WAs1Pob_5f8BgUmY8A</recordid><startdate>20200415</startdate><enddate>20200415</enddate><creator>Elshazli, Rami M.</creator><creator>Toraih, Eman A.</creator><creator>Elgaml, Abdelaziz</creator><creator>Kandil, Emad</creator><creator>Fawzy, Manal S.</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-3381-2641</orcidid></search><sort><creationdate>20200415</creationdate><title>Genetic polymorphisms of TP53 (rs1042522) and MDM2 (rs2279744) and colorectal cancer risk: An updated meta-analysis based on 59 case-control studies</title><author>Elshazli, Rami M. ; Toraih, Eman A. ; Elgaml, Abdelaziz ; Kandil, Emad ; Fawzy, Manal S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-7d52c2d7eff9753c1b5df49cad31590df8524b36dc722a305aa7a672da68bedb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Colorectal cancer</topic><topic>Colorectal Neoplasms - genetics</topic><topic>Genetic Predisposition to Disease</topic><topic>Humans</topic><topic>MDM2</topic><topic>Meta-analysis</topic><topic>Polymorphism, Single Nucleotide</topic><topic>Proto-Oncogene Proteins c-mdm2 - genetics</topic><topic>TP53</topic><topic>Tumor Suppressor Protein p53 - genetics</topic><topic>Variants</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Elshazli, Rami M.</creatorcontrib><creatorcontrib>Toraih, Eman A.</creatorcontrib><creatorcontrib>Elgaml, Abdelaziz</creatorcontrib><creatorcontrib>Kandil, Emad</creatorcontrib><creatorcontrib>Fawzy, Manal S.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Gene</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Elshazli, Rami M.</au><au>Toraih, Eman A.</au><au>Elgaml, Abdelaziz</au><au>Kandil, Emad</au><au>Fawzy, Manal S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Genetic polymorphisms of TP53 (rs1042522) and MDM2 (rs2279744) and colorectal cancer risk: An updated meta-analysis based on 59 case-control studies</atitle><jtitle>Gene</jtitle><addtitle>Gene</addtitle><date>2020-04-15</date><risdate>2020</risdate><volume>734</volume><spage>144391</spage><epage>144391</epage><pages>144391-144391</pages><artnum>144391</artnum><issn>0378-1119</issn><eissn>1879-0038</eissn><abstract>•A significant association of TP53 (rs1042522) polymorphism with increased CRC risk in overall pooled subjects under recessive model was observed.•An evidence of MDM2 (rs2279744) association with increased CRC risk in overall pooled subjects under dominant and heterozygote models was observed.•TP53 (rs1042522) and MDM2 (rs2279744) variants might represent candidate risk factors for CRC susceptibility.
Several earlier reports implicated TP53 (rs1042522) and MDM2 (rs2279744) variants in outcome of colorectal cancer (CRC), but with inconclusive findings. This current meta-analysis designed to uncover the role of these variants in CRC risk.
Two independent investigators extracted 59 eligible case-control studies from different electronic databases involving Scopus, Web of Science and PubMed prior to June 2019. Pooled odds ratios (ORs) and “95% confidence intervals (CIs)” were computed for different hereditary models. Stratification and heterogeneity analyses, and “Begg’s funnel plots” were conducted. In silico data analyses of the functional and structural properties of the study variants were applied.
In general, 47 and 16 case-control reports for TP53 (11,589 patients and 13,622 controls) and MDM2 (6841 CRC patients and 8792 healthy controls), respectively were enrolled in this meta-analysis. A significant association of TP53 (rs1042522) variant with increased CRC risk in overall pooled subjects under recessive model [(CC vs. GC + GG, OR = 1.134, 95% CI = 1.006–1.278, P = 0.039)] was observed. Moreover, an evidence of MDM2 (rs2279744) association with increased CRC risk in overall pooled subjects under dominant and heterozygote models [(TG + GG vs. TT, OR = 1.120, 95% CI = 1.003–1.250, P = 0.044) and (TG vs. TT, OR = 1.189, 95% CI = 1.076–1.313, P = 0.001), respectively] was reported. Additionally, TP53 (rs1042522) and MDM2 (rs2279744) showed an association with CRC risk among Asians and Africans under a recessive model, and among Asians under different genetic models, respectively, by stratification analysis.
TP53 (rs1042522) and MDM2 (rs2279744) variants might represent candidate risk factors for CRC susceptibility.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>32001373</pmid><doi>10.1016/j.gene.2020.144391</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-3381-2641</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0378-1119 |
| ispartof | Gene, 2020-04, Vol.734, p.144391-144391, Article 144391 |
| issn | 0378-1119 1879-0038 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2350095854 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Colorectal cancer Colorectal Neoplasms - genetics Genetic Predisposition to Disease Humans MDM2 Meta-analysis Polymorphism, Single Nucleotide Proto-Oncogene Proteins c-mdm2 - genetics TP53 Tumor Suppressor Protein p53 - genetics Variants |
| title | Genetic polymorphisms of TP53 (rs1042522) and MDM2 (rs2279744) and colorectal cancer risk: An updated meta-analysis based on 59 case-control studies |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T22%3A35%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Genetic%20polymorphisms%20of%20TP53%20(rs1042522)%20and%20MDM2%20(rs2279744)%20and%20colorectal%20cancer%20risk:%20An%20updated%20meta-analysis%20based%20on%2059%20case-control%20studies&rft.jtitle=Gene&rft.au=Elshazli,%20Rami%20M.&rft.date=2020-04-15&rft.volume=734&rft.spage=144391&rft.epage=144391&rft.pages=144391-144391&rft.artnum=144391&rft.issn=0378-1119&rft.eissn=1879-0038&rft_id=info:doi/10.1016/j.gene.2020.144391&rft_dat=%3Cproquest_cross%3E2350095854%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2350095854&rft_id=info:pmid/32001373&rft_els_id=S0378111920300603&rfr_iscdi=true |